• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[人工内分泌胰腺在临床中的应用]

[Use of the artificial endocrine pancreas in the clinic].

作者信息

Tsanev A, Zlateva S, Khristov V, Petkova M

出版信息

Vutr Boles. 1985;24(6):107-11.

PMID:4095982
Abstract

Via the artificial endocrine pancreas--apparatus "BIOSTATOR" 100 patients were studied and treated, namely: 90 with diabetes mellitus, 7 with hyperinsulinism and 3 with obesity. The 24-h insulin needs of the diabetics with insulin-dependent and non-insulin dependent with secondary exhaustion type of diabetes, were determined. The following subcutaneous insulin dosage was determined, depending on the insulin amount spent during the 24-h biostator control. It was established that the necessary reduction of the intravenously administered insulin is 30% on the average with the passing over to subcutaneous regime. The indices of lipid metabolism were also studied as well as numerous hormones with which the carbohydrate compensation leads to a change. The problem of the "morning" phenomenon is discussed.

摘要

通过人工内分泌胰腺——“生物调节器”设备对100名患者进行了研究和治疗,具体如下:90例糖尿病患者、7例高胰岛素血症患者和3例肥胖患者。测定了胰岛素依赖型和非胰岛素依赖型继发性衰竭型糖尿病患者24小时的胰岛素需求量。根据24小时生物调节器控制期间消耗的胰岛素量确定了以下皮下胰岛素剂量。结果表明,平均而言,过渡到皮下给药方案后,静脉注射胰岛素的必要减少量为30%。还研究了脂质代谢指标以及碳水化合物补偿导致变化的多种激素。讨论了“黎明”现象的问题。

相似文献

1
[Use of the artificial endocrine pancreas in the clinic].[人工内分泌胰腺在临床中的应用]
Vutr Boles. 1985;24(6):107-11.
2
[Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin].[胰岛素依赖型糖尿病患者在生物人工肝控制及皮下注射胰岛素期间的胰岛素需求]
Vutr Boles. 1990;29(1):74-7.
3
[Use of the endocrine artificial pancreas (GCIIS; Biostator) in heart surgery].[内分泌人工胰腺(葡萄糖控制胰岛素输注系统;生物人工胰腺)在心脏手术中的应用]
Minerva Med. 1982 Dec 22;73(49-50):3509-14.
4
[Dynamic changes in the hemostatic indices of diabetics during biostator control].
Vutr Boles. 1989;28(5):41-5.
5
Improvement of artificial endocrine pancreas (Biostator; GCIIS) performance combining feedback controlled insulin administration with a pre-programmed insulin infusion.
Horm Metab Res. 1982 Oct;14(10):505-7. doi: 10.1055/s-2007-1019062.
6
[Glucose-controlled insulin infusion systems (GCIIS, artificial pancreas) in therapy of diabetes mellitus and organic hyperinsulinism].[葡萄糖控制胰岛素输注系统(GCIIS,人工胰腺)在糖尿病和器质性高胰岛素血症治疗中的应用]
Verh Dtsch Ges Inn Med. 1987;93:309-12.
7
[Treatment of diabetes mellitus with an artificial pancreas].[人工胰腺治疗糖尿病]
Minerva Med. 1988 Apr;79(4):253-4.
8
[Use of the biostator (artificial pancreas) in the treatment of patients with diabetes mellitus].生物人工胰腺在糖尿病患者治疗中的应用
Klin Med (Mosk). 1984 Oct;62(10):55-60.
9
[Analysis of the daily insulin requirements as determined by a biostator (artificial pancreas) in patients with insulin-dependent diabetes mellitus].[通过生物调节器(人工胰腺)测定胰岛素依赖型糖尿病患者每日胰岛素需求量的分析]
Srp Arh Celok Lek. 1983 Sep-Oct;111(9-10):1351-60.
10
Optimal insulin delivery in diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar nonketotic coma (HHNC).糖尿病酮症酸中毒(DKA)和高血糖高渗非酮症昏迷(HHNC)中的最佳胰岛素给药。
Diabetes Care. 1982 May-Jun;5 Suppl 1:78-87.